MyRocky vs Maple (2026): Integrated GLP-1 Service vs General Telehealth

When Canadians search for an online GLP-1 prescription, two names appear repeatedly: MyRocky and Maple. The comparison is natural - both are well-funded, nationally recognised platforms operating inside Canadian regulatory frameworks. But placing them side by side obscures a fundamental strategic difference. MyRocky is a single-condition specialist. Maple is a general practice telehealth platform that happens to offer weight management alongside dozens of other conditions.

That specialisation versus breadth trade-off plays out in pricing structure, clinical depth, titration support, and long-term cost. A patient seeking a one-time GLP-1 prescription might experience both platforms similarly. A patient who requires six months of dose escalation, side-effect management, and regular check-ins will notice the difference quickly.

This comparison is structured to help you identify which platform fits your specific situation - whether you are starting from scratch, switching from an existing prescription, or evaluating ongoing program costs.

Platform Overview

Specialist vs General Telehealth

The case for a specialist platform rests on one argument: GLP-1 treatment is not simple. It involves multi-month titration from a starting dose to a therapeutic maintenance dose, management of gastrointestinal side effects during that window, regular weight and metabolic tracking, and - in many patients - dose adjustments based on individual response curves. None of that fits naturally into a general telehealth model built around acute care and one-off consults.

Maple was designed to put a physician on your screen within minutes for a cold, a UTI, or a renewal. It is genuinely excellent at that. Its 1-million-plus patient base is testament to the convenience of on-demand care. But the same architecture that makes Maple fast for acute visits creates friction for longitudinal management. Each dose escalation on a GLP-1 protocol requires a new appointment, a new assessment, and a new prescription - all billed separately.

MyRocky built its clinical workflow around the assumption that a GLP-1 patient will need multiple touchpoints over six months to a year, and it priced accordingly. That means the intake includes labs, the program includes structured follow-ups, and the pharmacy - which MyRocky owns - is coordinated with the prescribing team rather than operating independently.

Pricing Breakdown

The pricing difference between these two platforms is significant and becomes more pronounced the longer treatment continues. Maple's per-visit model is designed for episodic care; MyRocky's subscription model is designed for chronic condition management.

These estimates assume a patient who starts on a low dose, escalates twice over six months, and then maintains. Real-world patients who escalate more frequently, experience side-effect-driven dose reductions, or require additional clinical contact will find the gap widening further in MyRocky's favour. The one scenario where Maple may be cost-competitive is a patient who rarely needs clinical contact after an initial prescription - but that is the exception rather than the norm in GLP-1 treatment.

Province Coverage

Both platforms cover most of Canada. Maple operates in all provinces and has built considerable infrastructure around its 24/7 on-demand model nationally. MyRocky also serves all 10 provinces, with a particular emphasis on its Ontario base where its Mississauga pharmacy infrastructure is centred.

For territory residents, Maple's broader physician network gives it a marginal advantage. For the vast majority of patients in the ten provinces, coverage is effectively equivalent.

Clinical Support Depth

Maple connects patients with licensed physicians in real time - its response time for on-demand visits is often under ten minutes during peak hours. The physicians are general practitioners and specialists covering the full range of conditions Maple handles. For a GLP-1 consult, that means a qualified prescriber who can assess eligibility and write the prescription. However, those physicians are not GLP-1 specialists - they are generalists rotating through a high-volume telemedicine queue.

MyRocky's clinical team is different in character. Practitioners on the platform work specifically on weight management programs and are familiar with the nuances of semaglutide and tirzepatide titration - recognising when nausea indicates an overly aggressive escalation, when plateaus are expected versus concerning, and how to adjust protocols for patients with comorbidities. That depth of experience does not come from any single consultation; it accumulates across a program.

Maple also lacks lab bundling at intake. A MyRocky intake assessment typically includes baseline bloodwork review to confirm eligibility and establish a clinical baseline. On Maple, patients arrange their own labs separately, which adds friction and a potential gap in safety monitoring.

Titration and Follow-Up

GLP-1 titration on semaglutide typically proceeds from 0.25 mg weekly, escalating through 0.5 mg, 1 mg, and sometimes 2 mg or higher over three to six months. Each step requires clinical oversight: confirming the patient is tolerating the current dose, reviewing weight progress, and deciding whether to escalate, hold, or - in cases of significant side effects - reduce. This process is not complex, but it does require consistent access to a clinician who understands the treatment arc.

MyRocky schedules these check-ins automatically every four weeks as part of the program. Patients receive a prompt, complete a brief update, and the clinical team reviews it within the same cycle. No appointment booking required; no per-visit charge accruing. The titration proceeds on a defined schedule unless the clinical review indicates otherwise.

On Maple, the patient is responsible for initiating each follow-up. A motivated patient who remembers to book at the right interval will receive equivalent clinical oversight - but the burden of managing that schedule falls on the patient, not the platform. Patients who are new to GLP-1 treatment, managing other health conditions, or simply busy often miss the optimal window for a dose escalation, which lengthens the time to therapeutic dose and may reduce long-term outcomes.

Pros and Cons

Verdict

For a patient beginning a GLP-1 program and expecting to remain on treatment for six months or more, MyRocky is the more rational choice on both clinical and economic grounds. The specialist focus, bundled titration support, and in-house pharmacy create a coherent treatment experience that general telehealth platforms cannot replicate without substantially higher costs accruing over time.

Maple is the right tool when speed and breadth matter more than depth. A patient who already manages their GLP-1 through a specialist and needs Maple for an unrelated acute issue is using both platforms appropriately. A patient who turns to Maple as their primary GLP-1 provider because they recognise the brand will likely spend more, receive less structured titration support, and be responsible for coordinating their own dose escalation schedule - all of which are predictable friction points in a treatment that demands consistency.

The platforms are not in competition for the same patient profile. Maple excels at on-demand access for the full range of Canadian health needs. MyRocky excels at one specific task: getting a patient from a low starting GLP-1 dose to a therapeutic maintenance dose with minimum administrative friction and maximum clinical support. For that task, specialisation wins.

Sponsored link above. WeightLossInjections.ca may earn a commission if you purchase through this link at no additional cost to you. All editorial content is independent. GLP-1 medications require a valid prescription from a licensed Canadian physician.